Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7)
Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) (A2856-GRP)
Products
Description
Etrolizumab (Anti-Integrin a4b7) (ITGA4 & ITGB7) is a gut‐selective humanized monoclonal antibody targets β7 integrins with a potential to treat inflammatory bowel disease (IBD). MW: 144.3 KD.
Specifications
| Manufacturer | Selleck Chemicals LLC |
|---|---|
| Manufacturer Cat# | A2856 |
| Target | Interleukins |